Demography | “Hypo-flow” | “Hyper-flow” | p value |
---|---|---|---|
(n = 4) | (n = 8) | ||
Age in years | 40.0 ± 8.2 | 26.8 ± 13.8 | 0.1111) |
Male (%) | 2 (50.0) | 3 (37.5) | 1.0002) |
CD duration in years | 13.8 ± 7.8 | 3.9 ± 4.2 | 0.0811) |
Previous segmental resection, % | 0 | 0 | |
Disease location, n (%)* | 0.4912) | ||
L1 (distal 1/3 ileum ± limited cecal) | 0 (0.0) | 3 (37.5) | |
L3 (ileocolonic) | 4 (100.0) | 5 (62.5) | |
L4b (upper, distal to ligament of Treitz and proximal to distal 1/3 ileum) | 0 (0.0) | 0 (0.0) | |
Disease behavior, n (%)* | |||
B1 (nonstricturing, nonpenetrating) | 0 (0.0) | 0 (0.0) | |
B2 (stricturing) | 4 (100.0) | 8 (100.0) | |
B3 (penetrating) | 0 (0.0) | 0 (0.0) | |
B4 (structuring and penetrating) | 0 (0.0) | 0 (0.0) | |
Primary indication for surgery, n (%) | 1.0002) | ||
Recurrence of obstruction symptoms | 4 (100.0) | 7 (87.5) | |
Intractable disease | 0 (0.0) | 1 (12.5) | |
CDAI | 196.2 ± 73.8 | 198.2 ± 63.9 | 0.9631) |
C reactive protein (mg/dl) | 1.30 ± 2.01 | 0.47 ± 0.34 | 0.4661) |
Erythorocyte sedimentation rate (mm/h) | 32.0 ± 30.0 | 16.9 ± 14.3 | 0.2511) |
Preoperative therapy, n (%) | |||
5ASA | 4 (100.0) | 5 (62.5) | 0.4912) |
Elemental diet (>900 kcal) | 4 (100.0) | 7 (87.5) | 1.0002) |
TPN | 2 (50.0) | 3 (37.5) | 1.0002) |
CS (prednisolone) | 0 (0.0) | 4 (50.0) | 0.2082) |
AZA/6MP | 0 (0.0) | 4 (50.0) | 0.2082) |
Anti-TNF-α biologics | 1 (25.0) | 0 (0.0) | 0.3332) |
Antibiotics | 2 (50.0) | 3 (37.5) | 1.0002) |